MP37-14 PROGNOSTIC ROLE OF [ 11 C]CHOLINE PET/CT SCAN IN PATIENTS WITH METASTATIC CASTRATE RESISTANT PROSTATE CANCER UNDERGOING PRIMARY DOCETAXEL CHEMOTHERAPY

Abstract

You have accessJournal of UrologyProstate Cancer: Advanced (including Drug Therapy) III (MP37)1 Apr 2020MP37-14 PROGNOSTIC ROLE OF [11C]CHOLINE PET/CT SCAN IN PATIENTS WITH METASTATIC CASTRATE RESISTANT PROSTATE CANCER UNDERGOING PRIMARY DOCETAXEL CHEMOTHERAPY Masaya Jimbo*, Mohamed Ahmed, Jack Andrews, Manaf Alom, Ayca Dundar, R. Jeffrey Karnes, Alan Bryce, Ayse Kendi, Eugene Kwon, and Michael Bold Masaya Jimbo*Masaya Jimbo* More articles by this author , Mohamed AhmedMohamed Ahmed More articles by this author , Jack AndrewsJack Andrews More articles by this author , Manaf AlomManaf Alom More articles by this author , Ayca DundarAyca Dundar More articles by this author , R. Jeffrey KarnesR. Jeffrey Karnes More articles by this author , Alan BryceAlan Bryce More articles by this author , Ayse KendiAyse Kendi More articles by this author , Eugene KwonEugene Kwon More articles by this author , and Michael BoldMichael Bold More articles by this author View All Author Informationhttps://doi.org/10.1097/JU.0000000000000886.014AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVE: We sought to assess the prognostic utility of [11C]choline positron emission tomography/computed tomography (PET/CT) in patients with metastatic castrate resistant prostate cancer (mCRPC) undergoing primary docetaxel chemotherapy. METHODS: We performed a single institution retrospective analysis of 77 mCRPC patients who were treated with 6 cycles of docetaxel chemotherapy, and underwent [11C]choline PET/CT scans at baseline (prior to chemotherapy), mid-course (after 3 cycles), and post-therapy (after 6 cycles). We evaluated treatment response based on change in blood pool-corrected maximum standardized uptake value (SUVmax) of the index lesion on PET/CT, as well as change in serum prostate specific antigen (PSA). Logistic regression analysis was used to identify factors associated with complete treatment response. Progression free survival (PFS) analysis was performed using log-rank test and shown on Kaplan-Meier plot. RESULTS: Change in corrected SUVmax on mid-course scan was a significant predictor of complete response after full 6 cycles of docetaxel chemotherapy on univariable and multivariables analyses (Table). Patients with ≥20% reduction in corrected SUVmax on mid-course scan were 3.6 times more likely to achieve complete response, compared to patients with <20% reduction in corrected SUVmax (p = 0.0420). Change in PSA at mid-course was not a significant predictor of complete response. Median PFS in the complete response group was 34.0 months, compared to 9.5 months in the incomplete response group (p = 0.0014) (Figure). CONCLUSIONS: Our study showed that mid-course and post-therapy [11C]choline PET/CT evaluation for mCRPC patients undergoing primary docetaxel chemotherapy was able to predict full course treatment response and PFS, respectively. [11C]choline PET/CT should be considered as a valuable tool in the repertoire of the treating physician. Source of Funding: None © 2020 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 203Issue Supplement 4April 2020Page: e565-e566 Advertisement Copyright & Permissions© 2020 by American Urological Association Education and Research, Inc.MetricsAuthor Information Masaya Jimbo* More articles by this author Mohamed Ahmed More articles by this author Jack Andrews More articles by this author Manaf Alom More articles by this author Ayca Dundar More articles by this author R. Jeffrey Karnes More articles by this author Alan Bryce More articles by this author Ayse Kendi More articles by this author Eugene Kwon More articles by this author Michael Bold More articles by this author Expand All Advertisement PDF downloadLoading ...